Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fluit, A. C.
Right arrow Articles by Milatovic, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fluit, A. C.
Right arrow Articles by Milatovic, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 271-276
© 2002 The British Society for Antimicrobial Chemotherapy

In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci

A. C. Fluit*, F.-J. Schmitz, J. Verhoef and D. Milatovic

Eijkman-Winkler Center, UMCU, Room G04. 614, PO Box 85500, 3508 GA Utrecht, The Netherlands

Received 4 February 2002; returned 3 April 2002; revised 22 April 2002; accepted 8 May 2002

AZD2563 is a new oxazolidinone that has targeted activity against Gram-positive bacteria. The in vitro activity of AZD2563 and nine comparators against 1543 European enterococcal, staphylococcal and streptococcal isolates was determined. The compound is a potent oxazolidinone, with no isolate tested displaying an MIC > 4 mg/L and 94.4% having an MIC <=2 mg/L. Compared with linezolid, the distribution of MICs for all species of bacteria tested, with the exception of Enterococcus faecium, was shifted by one or two dilution steps to lower values for AZD2563. Thus, this oxazolidinone is a promising new antibiotic for the treatment of infections with Gram-positive cocci.

* Corresponding author. Tel: +31-30-2507630; Fax: +31-30-2541770; E-mail: A.C.Fluit{at}lab.azu.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. Yong, J. H. Yum, K. Lee, Y. Chong, S. H. Choi, and J. K. Rhee
In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria
Antimicrob. Agents Chemother., January 1, 2004; 48(1): 352 - 357.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. C. Fluit, F.-J. Schmitz, and D. Milatovic
The presence of ermB in Streptococcus pneumoniae has no influence on AZD2563 MIC values
J. Antimicrob. Chemother., January 1, 2003; 51(1): 184 - 185.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.